Fluidigm (FLDM) Tops Q2 EPS by 8c; Guides Q3 Below Street

Fluidigm (NASDAQ: FLDM) reported Q2 EPS of ($0.12), $0.08 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $31 million versus the consensus estimate of $30.57 million.

“Second quarter results were driven by a rebound in our base business and early customer orders following the launch of our new fourth generation CyTOF® XT mass cytometry product,” said Chris Linthwaite, President and CEO. “Our services business continues to execute well despite a challenging operating environment.

“The steady improvement in our base business performance reflects the favorable impact of our focus on innovation and partnership. We have an exciting pipeline of new customer opportunities and new products. The emergence of the Delta variant remains a wildcard in terms of testing revenue in the months ahead, but our thesis that we are well-equipped to address the biggest trends in health care remains intact, as evidenced by further penetration of translational and clinical research programs and influential consortia,” continued Linthwaite.

GUIDANCE:

Fluidigm sees Q3 2021 revenue of $29-31 million, versus the consensus of $33.92 million.

For earnings history and earnings-related data on Fluidigm (FLDM) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Glacier Bancorp (GBCI) Misses Q1 EPS by 3c
• Marten Transport (MRTN) Misses Q1 EPS by 2c